Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial

Chin J Integr Med. 2021 Dec;27(12):891-895. doi: 10.1007/s11655-021-3448-9. Epub 2021 Aug 25.

Abstract

Background: The side effects of chemotherapy-induced nausea and vomiting (CINV) and myelosuppression reduce the cancer patients' adherence to chemotherapy. Many Chinese patients choose Chinese medicine (CM) during chemotherapy to reduce side effects; however, the evidence is lacking. The efficacy of a CM herbal treatment protocol, Jianpi Bushen Sequential Formula (, JBSF) will be evaluated on chemotherapy completion rate among patients with colon cancer.

Methods: A multi-center double-blind randomized controlled trial (RCT) will be conducted on 400 patients with colon cancer who will receive 8 cycles of adjuvant chemotherapy with oxaliplatin and capecitabine (CAPEOX). Patients will be randomized 1:1 to receive the JBSF or placebo formula. The primary outcome is the overall chemotherapy completion rate. The secondary outcomes include individual chemotherapy completion rate, 4-cycle completion rate of chemotherapy, time to treatment failure, relative dose intensity and treatment toxicity. Follow-up visits will be scheduled before every and after last chemotherapy.

Discussion: This study will provide evidence on whether JBSF can improve the chemotherapy completion rate and reduce side effects among patients with colon cancer. (Trial registration: ClinicalTrials.gov, No. NCT03716518).

Keywords: Chinese medicine; Jianpi Bushen Sequential Formula; Liujun Anwei Formula; Qitu Erzhi Formula; chemotherapy induced nausea and vomiting; colon cancer; myelosuppression.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Chemotherapy, Adjuvant
  • Colonic Neoplasms* / drug therapy
  • Double-Blind Method
  • Humans
  • Multicenter Studies as Topic
  • Nausea
  • Quality of Life*
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Vomiting

Associated data

  • ClinicalTrials.gov/NCT03716518